TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
Geoffrey R. Oxnard, J.C.-H. Yang, Helena A. Yu, Seung‐Whan Kim, Hideo Saka, Leora Horn, Kōichi Goto, Yuichiro Ohe, Helen Mann, Kenneth S. Thress, Melanie M. Frigault, Karthick Vishwanathan, Dana Ghiorghiu, Suresh S. Ramalingam, Myung‐Ju Ahn
Topics & Concepts
OsimertinibMedicineDurvalumabSelumetinibLung cancerOncologyInternal medicineCancerNivolumabAdenocarcinomaImmunotherapyKRASROS1Colorectal cancerLung Cancer Treatments and MutationsFibroblast Growth Factor ResearchRadiomics and Machine Learning in Medical Imaging